diphtheria + tetanus + pertussis + polio + haemophilus influenza type b + varicella + measles-Insel Gruppe AG, University Hospital Bern-tetanus-Haemophilus influenzae type b infection-hepatitis B

This entry describes a comprehensive revaccination protocol implemented by Insel Gruppe AG and the University Hospital Bern for patients with B-cell malignancies who have undergone chimeric antigen receptor T-cell (CAR-T) therapy. CAR-T cell therapy often results in the depletion of healthy B cells and plasma cells, leading to a significant loss of humoral immunity and protection against vaccine-preventable diseases. The protocol, evaluated in the IMCAR study (NCT05681390), utilizes a series of standard vaccines to restore immunity against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b, hepatitis B, measles, and varicella. The regimen typically involves the administration of commercial vaccines such as INFANRIX DTPa-IPV+Hib, Engerix B, Priorix, and Varilrix at specific time points (e.g., 6 and 12 months) post-CAR-T infusion. This structured approach is designed to rebuild immune defenses and mitigate the risk of severe infections in this highly immunocompromised patient population.

Brand names

Infanrix DTPa-IPV+HibVarilrixPriorix

Other names

IMCAR vaccination protocolVaccine Immunity Restoration After CAR-T